...
首页> 外文期刊>Pharmacoepidemiology and drug safety >Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004.
【24h】

Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004.

机译:1997年至2004年,医院和医生在心肌梗死后开始二级预防的变化。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: Myocardial infarction (MI) survivors benefit from receiving secondary prevention, including beta-blockers, angiotensin-blocking agents, and statins, as recommended by guidelines. Compliance with these guidelines is suboptimal. We sought to describe the initiation of secondary prevention in MI survivors, and to describe the variation in initiation by discharging the hospital, the physician, and the physician "responsible" for secondary prevention prescribing decisions in British Columbia in 1997-2004. METHODS: We assembled a cohort of 28,613 patients discharged alive from the hospital after their first MI and were not readmitted within 30 days. Physicians responsible for prescribing post-MI secondary prevention medications were identified as the physicians prescribing the greatest number of cardiac medications (post-discharge cardiac prescribers). We used multilevel logistic regression to assess the variation in drug initiation at discharging hospital, discharging physician, and post-discharge cardiac prescriber levels, which were adjusted for patient and provider characteristics during the study period. RESULTS: Beta-blockers initiation increased from 56 to 71% over the 8-year study period; angiotensin-converting enzyme/angiotensin II receptor blocker initiation increased from 37 to 70%, and statin initiation increased from 22 to 66% (0-28% for high-potency statins). The probability for initiating an average patient with the study drugs varied widely in age-sex-adjusted models at the hospital and physician levels. Further adjustment did not meaningfully change findings. The variation was largest for statins. The maximum between-provider variance was found for high-potency statins in 2003-2004 at the post-discharge cardiac prescriber level. CONCLUSIONS: Study-drug initiation is increasing among MI survivors, but the variation in initiation is wide between discharging hospitals and physicians.
机译:目的:按照指南的建议,心肌梗死(MI)幸存者可从接受二级预防中受益,包括β受体阻滞剂,血管紧张素阻滞剂和他汀类药物。遵守这些准则不是最理想的。我们试图描述在MI幸存者中开始二级预防的方法,并描述出院,医师和负责“二级预防”处方决定的医生(负责人)在1997-2004年间的启动变化。方法:我们收集了28,613例首次出现MI后从医院复活并在30天内未重新入院的患者。确定负责开出MI后二级预防药物的医师是开出最多心脏药物(出院后心脏处方)的医师。我们使用多级logistic回归评估出院时,出院医师和出院后心脏处方者水平的药物启动变化,在研究期间已针对患者和提供者的特征对其进行了调整。结果:在8年的研究期内,β受体阻滞剂的启动率从56%上升至71%;血管紧张素转换酶/血管紧张素II受体阻滞剂的起始比例从37%增至70%,他汀类药物的起始比例从22%增至66%(高效力他汀类药物为0-28%)。在医院和医师水平上,按年龄进行性别调整的模型中,启动研究药物的普通患者的可能性差异很大。进一步的调整并没有有意义地改变发现。他汀类药物的变化最大。 2003年至2004年,在出院后心脏处方者水平上发现了高效他汀类药物的最大供应商差异。结论:MI幸存者中研究药物的启动正在增加,但出院医院和医师之间的启动差异很大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号